semaglutide
3% Drop in Obesity Bills with Semaglutide
3% Drop in Obesity Bills with Semaglutide Semaglutide generally costs less out-of-pocket than tirzepatide, saving patients hundreds of dollars each month. In 2024 the FDA proposed removing three GLP-1 drugs from the 503B bulks list, a move that could tighten supply chains and keep prices from rising further (FDA). The